https://www.investing.com/news/stock-market-news/edwards-lifesciences-cut-to-equal-weight-at-wells-fargo-on-limited-upside-to-tavr-market-growth-432SI-3025145

Edwards Lifesciences (EW) trended lower in the pre-market Wednesday after Wells Fargo downgraded the MedTech company citing concerns about its topline growth. Read the full story here.

Edwards Lifesciences Corporatio - Consensus Indicates Potential 12.3% Upside

https://www.investing.com/news/pro/wells-fargo-downgrades-edwards-lifesciences-to-equal-weight-432SI-3024682

Edwards Lifesciences Corporation (NYSE:EW) shares, rose in value on Friday, March 03, with the stock price up by 1.36% to the previous day’s close as strong demand from buyers drove the stock to $81.32. Actively observing the price movement in the recent trading, the stock is buoying the session at $80.23, falling within a range … Read This First Before You Buy Edwards Lifesciences Corporation (NYSE: EW) Stock Read More »

Currently, Edwards Lifesciences Corporation’s (EW) stock is trading at $81.24, marking a gain of 1.26% from last night’s close. At this price, the stock is -38.03% below its 52-week high of $131.10 and 21.02% above its 52-week low of $67.13. Based on the past 30-day period, the stock price is -0.50% below the high and […]

In today’s recent session, 1.72 million shares of the Edwards Lifesciences Corporation (NYSE:EW) have been traded, and its beta is 1.02. Most recently the company’s share price was $79.96, and it changed around $2.62 or 3.38% from the last close, which brings the market valuation of the company to $47.87B. EW at last check was … Why Edwards Lifesciences Corporation (NYSE: EW) Stock Should Not Be Taken For Granted By Investors In 2023 Read More »

https://www.investing.com/news/pro/cicc-starts-edwards-lifesciences-at-outperform-432SI-3011885

WESTMINSTER, CA / ACCESSWIRE / February 20, 2023 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its subsidiary Clyra Medical Technologies, Inc. has added two medical industry veterans as new members of its board of directors: Nicholas Valeriani and Linda Park. Nicholas Valeriani has decades of executive experience in the medical device industry. He spent 34 years at Johnson & Johnson, where he led several corporate functions and was a member of its executive committee. Key positions included corporate vice president of human resources, worldwide chairman of medical devices & diagnostics, and Vice President in the Office of Strategy and Growth. He currently serves on the board of directors for Edwards Lifesciences, Surgalign, Inc., SPR Therapeutics, and AgNovos Bioscience. Mr. Valeriani also serves on the board of the Gary and Mary West Health Institute, an independent non-profit medical research organization whose mission is to enable seniors to successfully age in place with access to high quality, affordable healthcare and support services.

In recent trading session, Edwards Lifesciences Corporation (NYSE:EW) saw 1.07 million shares changing hands at last check today with its beta currently measuring 1.02. Company’s recent per share price level of $77.00 trading at -$0.28 or -0.36% at last check today assigns it a market valuation of $47.83B. That most recent trading price of EW’s … Edwards Lifesciences Corporation (NYSE:EW) Shares Dropped -0.26% In A Week. Can It Continue Rising? Read More »

Edwards Lifesciences Corporation (NYSE:EW) shares, rose in value on Friday, 02/10/23, with the stock price down by -0.10% to the previous day’s close as strong demand from buyers drove the stock to $77.20. Actively observing the price movement in the last trading, the stock closed the session at $77.28, falling within a range of $76.8038 … Is Edwards Lifesciences Corporation (NYSE: EW) A Stock A New Investor Should Consider Now? Read More »

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enrapturing stocks: Edwards Lifesciences Corporation (NYSE:EW -2.45%), Weyerhaeuser Company (NYSE:WY -0.79%) appeared first on Stocks Equity .

In today’s recent session, 0.81 million shares of the Edwards Lifesciences Corporation (NYSE:EW) have been traded, and its beta is 1.03. Most recently the company’s share price was $79.36, and it changed around -$0.68 or -0.85% from the last close, which brings the market valuation of the company to $50.93B. EW at last check was … Edwards Lifesciences Corporation (NYSE: EW) Stock Forecast: Bullish Signals Pointing To $100.00 In 2023 Read More »

Edwards Lifesciences Corporatio - Consensus Indicates Potential 11.9% Upside

Raymond James has downgraded Edwards Lifesciences (EW) to market perform from outperform due to concerns over slowing growth for transcatheter aortic valve replacements (TAVR).

Raymond James softens on Edwards Lifesciences as confidence in growth profile begins to fade

https://www.investing.com/news/pro/raymond-james-downgrades-edwards-lifesciences-to-market-perform-432SI-2995779

More recently, Edwards Lifesciences TAVR performance has been volatile. Check out why we would likely look to add to our EW positions if the stock traded down.

In the current trading session, Edwards Lifesciences Corporation’s (EW) stock is trading at the price of $82.67, a fall of -2.18% over last night’s close. So, the stock is trading at a price that is -36.94% less than its 52-week high of $131.10 and 23.15% better than its 52-week low of $67.13. Based on the […]

Edwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call dated Jan. 31, 2023. Corporate Participants: Mark Wilterding — Senior Vice President, Investor Relations and Treasurer Michael Mussallem — Chairman and Chief Executive Officer Scott Ullem — Corporate […] The post Edwards Lifesciences Corporation (EW) Q4 2022 Earnings Call Transcript first appeared on AlphaStreet .

Edwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call dated Jan. 31, 2023.

https://www.investing.com/news/pro/cfra-upgrades-edwards-lifesciences-to-buy-432SI-2993515

Wednesday''s top analyst upgrades and downgrades included Alphabet, Bank of America, Dollar General, Edwards Lifesciences, Fortinet, Fox, Halliburton, LyondellBasell Industries, Paramount Global, SoFi Technologies and Truist Financial.

Edwards Lifesciences Corporatio with ticker code (EW) now have 21 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 128 and 68 with the average target price sitting at 90.38. With the stocks previous close at 76.06 this would imply there is a potential upside of 18.8%. There is a 50 day moving average of 75.69 and the 200 moving average now moves to 89.65. The market cap for the company is $47,421m. Find out more information at: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $56,349m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Edwards Lifesciences Corp (NYSE: EW ) reported Q4 adjusted EPS of $0.64 , up 25% Y/Y and higher than the consensus of $0.61. The company reported Q4 revenues of $1.35 billion, up 1% and 7% on constant currency, beating the consensus of $1.33 billion. While TAVR sales remained flat year over year, Edwards … Full story available on Benzinga.com

https://www.investing.com/news/pro/edwards-lifesciences-pt-raised-to-84-at-evercore-isi-432SI-2992782

Edwards Lifesciences Corp (NYSE:NYSE:EW) Q4 2022 Earnings Conference Call January 31, 2023 5:00 PM ETCompany ParticipantsMark Wilterding - VP, IRMichael Mussallem - Chairman & CEOScott…

WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) revealed earnings for its fourth quarter that increased from the same period last year and beat the Street estimates.The company''s bottom lin…

https://www.investing.com/news/stock-market-news/edwards-lifesciences-cut-to-underperform-at-bernstein-as-organic-growth-slows-432SI-2992379

Edwards Lifesciences (EW) is scheduled to announce Q4 earnings results on Tuesday, January 31st, after market close.The consensus EPS Estimate is $0.61 (+19.6% Y/Y) and the…

https://www.investing.com/news/stock-market-news/3-reasons-edwards-lifesciences-was-downgraded-at-piper-sandler-today-432SI-2991524

Edwards Lifesciences Corporation (NYSE:EW) price is hovering lower on Monday, January 30, dropping -2.18% below its previous close. A look at today’s price movement shows that the recent level at last check reads $78.14, with intraday deals fluctuating between $77.81 and $78.84. The company’s 5Y monthly beta was ticking 1.01 while its P/E ratio in … Edwards Lifesciences Corporation (NYSE: EW) Continues To Point Downwards Read More »

Edwards Lifesciences (NYSE: EW ) is set to give its latest quarterly earnings report on Tuesday, 2023-01-31. Here''s what investors need to know before the announcement. Analysts estimate that Edwards Lifesciences will report an earnings per share (EPS) of $0.61. Edwards Lifesciences bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com

Edwards Lifesciences (EW) fell more than ~1% pre-market Monday after Piper Sandler downgraded the heart device maker to Neutral from overweight. Read the full story here.

https://www.investing.com/news/pro/piper-sandler-downgrades-edwards-lifesciences-to-neutral-432SI-2990797